Catecholamines and behaviour

STEPHEN T. MASON
Department of Psychology, Brunel University, London

CAMBRIDGE UNIVERSITY PRESS
Cambridge
London New York New Rochelle
Melbourne Sydney
Contents

Preface xi
Permissions xiii
Abbreviations xv

1 Anatomy of the catecholamine systems in the brain 1
  Introduction 1
  Noradrenaline 2
  Dopamine 5
  Further reading 7
  References 7

2 Pharmacological manipulation of catecholamine systems 9
  Introduction 9
  Lesions and synthesis inhibition 9
    Tyrosine hydroxylase inhibitors 10
    DBH inhibitors 10
    Electrolytic lesion 11
    6-Hydroxydopamine 11
  Stimulation 12
    Precursor administration 14
    Direct receptor agonists 14
    Electrical stimulation 15
  Recording 15
    Single units 16
    Release and push–pull 16
  Conclusion 17
  Further reading 17

3 Catecholamines and intracranial self-stimulation behaviour 18
  Introduction 18
Contents

The paradigm 18
Its significance 20
Early evidence for catecholamine involvement 20
  Precursor administration 20
  Synthesis inhibition 22
  Neurotoxic lesions 24
  Summary 25
Noradrenaline and ICSS 25
  Mapping studies 25
  Noradrenaline release during ICSS 30
  Noradrenergic drugs and ICSS 37
  Synthesis inhibitors 43
  6-Hydroxydopamine lesions 46
  Conclusion 53
Dopamine and ICSS 54
  Mapping studies 54
  Dopamine release during ICSS 57
  Dopaminergic drugs and ICSS 59
  Interactions with other systems 69
  Intracerebral localisation 72
  Performance versus reward 75
  6-OHDA lesion 82
  Conclusion 87
References 88

4 Catecholamines and motor behaviour 96
Introduction 96
  The paradigm 96
Early evidence for catecholamine involvement 99
  Precursor administration 99
  Inhibition of breakdown 102
  False transmitters 103
  Synthesis inhibitors and reserpine 103
Noradrenaline and motor behaviour 104
  Agonist drugs 104
  Antagonist drugs and synthesis inhibitors 108
  6-OHDA lesions 109
  Noradrenaline and rotation 113
  Interactions with other systems 115
  Summary 119
Dopamine and motor behaviour 121
  Introduction 121
  Dopamine agonists 121
  Dopamine antagonists 126
5 Catecholamines and learning behaviour 177
   Introduction 177
      The paradigm 177
   Early evidence for catecholamine involvement 178
      L-DOPA and MAOIs 178
      Synthesis inhibition with AMPT 180
      Early 6-OHDA lesions 183
      Catecholamine release/levels after learning 185
   Conclusions from early experiments 191
   Noradrenaline and learning behaviour 192
      Agonist drugs 192
      Antagonist drugs 196
      Synthesis inhibitors 197
      Lesions of noradrenergic systems 205
      6-OHDA lesions and learning 211
      Ventral bundle lesions 225
      Cerebellar projection 226
      Self-administration 226
      Interaction with other systems 228
   Summary 230
   Dopamine and learning behaviour 231
      Agonists 231
      Antagonists 233
      6-OHDA lesions 238
      Self-administration 241
      Interactions with other systems 243
   Summary 244
   Conclusions 245
References 245

6 Catecholamines and cognitive behaviour 260
   Introduction 260
   Noradrenaline and cognitive behaviour 260
      Extinction 260
      Mechanisms of the DBEE 269
Contents

Selective attention 277
Fear and anxiety 285
Frustration and nonreward 290
Summary 295
Dopamine and cognitive behaviour 296
Attention 296
Incentive motivation 303
Secondary conditioning 304
Summary 308
References 309

7 Catecholamines and vegetative behaviour 316
Introduction 316
Catecholamines and sleep 316
Noradrenaline 316
Dopamine 326
Summary 328
Catecholamines and aggression 329
Noradrenaline 329
Dopamine 339
Summary 341
Catecholamines and sexual behaviour 341
Noradrenaline 341
Dopamine 345
Summary 347
Catecholamines and eating behaviour 347
Noradrenaline 347
Dopamine 363
Catecholamines and drinking behaviour 370
Noradrenaline 370
Dopamine 372
Summary 372
References 373

8 Catecholamines and pathological behaviour 388
Introduction 388
Limitations of clinical studies 389
I Cognitive disorders 392
Schizophrenia 392
Introduction 392
Noradrenaline 392
Dopamine 397
Alzheimer’s disease and (pre)senile dementia 400
Introduction 400
Contents

Noradrenaline 400
Korsakoff’s psychosis 403
  Introduction 403
  Noradrenaline 403
  Conclusion 404
Attentional deficit disorder 404
  Introduction 404
  Noradrenaline 404
  Dopamine 405
  Drug effects 406
  Conclusion 406
Summary – cognitive disorders 406
  Schizophrenia 406
  Senile dementia – Alzheimer’s disease 407
  Korsakoff’s psychosis 408
  Attentional deficit disorder 408
II  Movement disorders 408
Parkinsonism 408
  Introduction 408
  Dopamine 409
  Noradrenaline 410
  Conclusion 411
Huntington’s chorea 412
Epilepsy 412
  Introduction 412
  Noradrenaline 413
  Dopamine 417
  Conclusion 417
Summary – movement disorders 418
  Parkinson’s disease 418
  Huntington’s chorea 418
  Epilepsy 418
III  Mood disorders 419
Depression 419
  Introduction 419
  Noradrenaline 420
  Dopamine 422
Anxiety 424
  Introduction 424
  Noradrenaline 424
Mania 425
  Noradrenaline 425
Summary – mood disorders 426
  Depression 426
<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety</td>
<td>427</td>
</tr>
<tr>
<td>Mania</td>
<td>427</td>
</tr>
<tr>
<td>Conclusions</td>
<td>427</td>
</tr>
<tr>
<td>Disease or symptoms?</td>
<td>427</td>
</tr>
<tr>
<td>References</td>
<td>428</td>
</tr>
<tr>
<td>Epilogue</td>
<td>444</td>
</tr>
<tr>
<td>Appendix: Behavioural terms and paradigms</td>
<td>445</td>
</tr>
<tr>
<td>Index</td>
<td>451</td>
</tr>
</tbody>
</table>